关于多发性硬化<\/u><\/b> <\/p> \n
多发性硬化是一种以中枢神经系统炎性脱髓鞘病变为主要特点的免疫介导性疾病，其病因尚不明确，可能与遗传、环境、病毒感染等多种因素相关[1]<\/sup>。髓鞘损伤会干扰大脑与身体其他部位之间的通信[3]<\/sup>，最终导致神经退行性损害，这一过程目前尚不可逆[10]<\/sup>。<\/p> \n 复发型多发性硬化包括临床孤立综合征、复发-缓解型疾病和活动性继发进展型疾病[11]<\/sup>。其中，复发-缓解型疾病是诊断时最常见的类型，80%-85%的患者初诊时被诊断为复发-缓解型疾病，其表现为明显的复发和缓解过程，每次发作后均基本恢复，不留或仅留下轻微后遗症[1]<\/sup>。约10%-15%的患者被诊断为进展型疾病[11]<\/sup>。<\/p> \n 关于热珀西亚<\/u><\/b>®<\/sup><\/u><\/b>（盐酸奥扎莫德胶囊）<\/u><\/b><\/p> \n 热珀西亚<\/i>是一种口服鞘氨醇1-磷酸（S1P）受体调节剂，可高亲和力结合S1P受体1和5（S1P1<\/sub>和S1P5<\/sub>）[12]<\/sup>。热珀西亚<\/i>可适度抑制淋巴细胞迁出，减少外周血中淋巴细胞数量[7]<\/sup>。热珀西亚<\/i>对多发性硬化发挥治疗作用的机制尚不完全明确，可能与减少淋巴细胞向中枢神经系统的迁移相关[7]<\/sup>。<\/p> \n 热珀西亚<\/i>已在全球多个国家和地区批准用于治疗成人复发型多发性硬化症和中度至重度活动性溃疡性结肠炎成人患者。<\/p> \n 注：热珀西亚溃疡性结肠炎适应症尚未在中国获批<\/i><\/p> \n [1]《多发性硬化诊断和治疗中国专家共识（2018版）》，中国神经免疫学和神经病学杂志2018年11月第25卷第6期 Chin J Neuroimmunol & Neurol 2018，Vol.25，No.6，387:394 <\/p>"];
$("#dvExtra").html(content_array[0]);})();
<\/sup>[2] National Multiple Sclerosis Society. Definition of MS. www.nationalmssociety.org\/What-is-MS\/Definition-of-MS<\/a>. Accessed on March 25, 2020<\/span>.
<\/sup>[3] National Multiple Sclerosis Society. What is Myelin? www.nationalmssociety.org\/What-is-MS\/Definition-of-MS\/Myelin<\/a>. Accessed March 25, 2020<\/span>.
<\/sup>[4] Manca R, et al. J Neurol Sci. 2018;388:115-127.
<\/sup>[5] Sumowski JF, et al. Neurology. 2018;90:278-288
<\/sup>[6] Campbell J, et al. Postgrad Med J. 2017;93(1097):143-147.
<\/sup>[7] Deloire, et al. Multiple Sclerosis 2010;16:581–587. <\/sup>
[8] Comi, G, Kappos, L, Selmaj, KW, et at. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicenter, randomized, minimum 12-month, phase 3 trial. The Lancet: Neurology. DOI: 10.1016\/S1474-4422(19)30239-X.
<\/sup>[9] Cohen, JA, Comi, G, Selmaj, KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicenter, randomized, 24-month, phase 3 trial. The Lancet: Neurology. DOI: 10.1016\/S1474-4422(19)30238-8.
<\/sup>[10] National Multiple Sclerosis Society. What Causes MS? www.nationalmssociety.org\/What-is-MS\/What-Causes-MS<\/a>. Accessed March 25, 2020<\/span>.
<\/sup>[11] National Multiple Sclerosis Society. Types of MS. www.nationalmssociety.org\/What-is-MS\/Types-of-MS<\/a>. Accessed March 25, 2020<\/span>.
<\/sup>[12] ZEPOSIA (ozanimod) capsules for oral use. Bristol Myers Squibb Pharmaceutical Corporation. Full prescribing information. 3\/2020.<\/sup><\/p> \n